Full Text View
Tabular View
No Study Results Posted
Related Studies
Molecular Analysis of Breast Cancer
This study is currently recruiting participants.
Study NCT00569049   Information provided by Stanford University
First Received: December 4, 2007   Last Updated: November 19, 2008   History of Changes

December 4, 2007
November 19, 2008
May 1996
 
 
 
Complete list of historical versions of study NCT00569049 on ClinicalTrials.gov Archive Site
 
 
 
Molecular Analysis of Breast Cancer
Molecular Analysis of Breast Cancer

This is a research-based study that is looking at the biologic features of breast tissue, lymph node tissue, or blood in order to study breast cancer development growth, and spread. Through tissue and/or blood samples we hope to gain further knowledge and understanding of how to improve diagnosis and treatment of breast cancer by identifying the molecular markers that predict clinical outcome and response to therapy.

The tissue obtained in this protocol will be used for genome-wide examination of DNA, RNA expression profiling, proteomic analyses, isolation and analyses of normal and cancer stem cells, isolation and analyses of circulating tumor cells, possible analyses of immune cells, and possible analyses of serum factors. The tissue may also be used to develop patient-specific cell culture models or mouse xenograft models of breast cancer for biologic study of tumor progression and metastases and for therapeutic testing. In general, the tissue will be used in studies that will molecularly classify tumors, identify prognostic markers, identify potential therapeutic markers, identify potential treatment targets, and help us better understand the biology and specific role played by different tumor cells in the metastatic process.

The ultimate goal is to use molecular analyses to improve the diagnosis and treatment of breast cancer.

 
Observational
Other
Breast Cancer
Procedure: breast tissue, lymph node tissue or blood
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
99999
 
 

Inclusion Criteria:People eligible for this study include anyone older than 18 years who is undergoing one of the following procedures: core needle or surgical breast biopsy, lumpectomy, mastectomy, axillary lymph node surgery, breast reduction surgery, or ductal lavage or ductoscopy. Patients who have had breast cancer in the past who are currently free of disease or who have a breast cancer recurrence are also eligible. All patients who participate must be able to understand and sign the informed consent. Although most patients will be female, any males undergoing the above procedures are also eligible for this study.
 Exclusion Criteria:Any patient who is less than 18 years old, who is unable to understand the informed consent, or not undergoing the above procedures will be excluded from this research.

Female
18 Years and older
Yes
 
United States
 
NCT00569049
 
SU-11052007-799, 1028313-100-JAACC, 1045090-101-KBAHQ, 10EB-10086; 11IB-0175, 75026, 8EB-1106, BRSNSTU0001, CA085129; 1R01CA109325-01, NCT00569049
Stanford University
  • National Institutes of Health (NIH)
  • University of California
  • BCRP (of CA) - Breast Cancer Research Program
  • Warnock Research Fund
  • Breast Cancer Research Foundation
Principal Investigator: Stefanie S. Jeffrey M.D. Stanford University
Stanford University
November 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP